Kazakhstan prepares second site for production of COVID-19 vaccines

Deputy Prime Minister Yeraly Tugzhanov, within the framework of the instructions of the Head of State to ensure the country's biosafety, indicated in the Address to the people of Kazakhstan, got acquainted with the work of Antigen Research and Production Enterprise.

Currently, this enterprise is a partner of the Scientific Research Institute of Biological Safety Problems of the Ministry of Education and Science of the Republic of Kazakhstan.

The Research Institute, using the Antigen site, prepared and put into operation the second production site for the full production cycle of medical vaccines, including QazVac.

For these purposes, with the support of the Akimat of the Almaty Region, new technological equipment for the production of vaccines was purchased on concessional lending.

In September 2021, the Antigen site has already produced 300,000 validation series of QazVac vaccines with a capacity of up to 1 million doses per month.

International quality standards enable the company to achieve a high technical level, quality and reliability in all areas of production.

Antigen, along with a biopharmaceutical plant under OtarBioPharm LLP, has become the second production site for the production of the Kazakh QazVac vaccine developed by the Research Institute.

Stay updated about the events of the Prime Minister and the Government of Kazakhstan - subscribe to the official Telegram channel